tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Venture Life CEO Exercises Options as Group Updates Total Voting Rights

Story Highlights
  • Venture Life’s CEO exercised options over 483,333 shares, lifting his stake to about 2.13%.
  • New share issuance sets Venture Life’s total voting rights at 126,997,164 for disclosure purposes.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Venture Life CEO Exercises Options as Group Updates Total Voting Rights

Claim 70% Off TipRanks Premium

Venture Life ( (GB:VLG) ) has provided an announcement.

Venture Life Group has issued 483,333 new ordinary shares following the exercise of share options by chief executive Jerry Randall under the company’s Long-Term Incentive Plan, at an exercise price of 41 pence per share, increasing his beneficial holding to 2,736,533 shares, or about 2.13% of the company’s issued share capital. The new shares are expected to be admitted to trading on AIM on 7 January 2025, taking the total shares in issue to 128,737,145, of which 1,739,981 are held in treasury, and setting the company’s voting rights at 126,997,164, a reference figure for investors monitoring disclosure thresholds under UK market transparency rules.

The most recent analyst rating on (GB:VLG) stock is a Hold with a £66.00 price target. To see the full list of analyst forecasts on Venture Life stock, see the GB:VLG Stock Forecast page.

Spark’s Take on GB:VLG Stock

According to Spark, TipRanks’ AI Analyst, GB:VLG is a Neutral.

Venture Life’s stock score is primarily supported by strong technical indicators and positive corporate events, such as share buybacks and insider buying, which suggest confidence in future prospects. However, the high P/E ratio and profitability challenges weigh down the score, indicating potential overvaluation and financial risks.

To see Spark’s full report on GB:VLG stock, click here.

More about Venture Life

Venture Life Group is a UK-headquartered international consumer self‑care company operating in the global consumer healthcare sector. Its portfolio spans women’s intimate healthcare (Balance Activ), ENT care (Earol), energy and glucose management products (Lift and Glucogel) and the Health & Her range for the hormonal lifecycle, sold through pharmacies, health and beauty retailers, grocery multiples and e-commerce, both directly in key markets such as the UK, Ireland and the US and via international distribution partners elsewhere.

Average Trading Volume: 191,413

Technical Sentiment Signal: Buy

Current Market Cap: £83.5M

See more data about VLG stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1